Kimball Q1 Sales Up 7% but EPS Falls to $0.11 as Costs Bite; FY27 Sales Seen at High End
KE sits 23% above its 52-week low of $21.01.
Summary
Kimball returned to top-line growth in fiscal Q1 2027, with net sales of $390.8M up 7% year-over-year, but profitability deteriorated sharply. Diluted EPS fell to $0.11 from $0.40 a year ago and adjusted diluted EPS dropped to $0.25 from $0.49, as selling and administrative expenses jumped to $18.1M from $13.1M and the tax provision rose to $5.2M from $0.9M. Operating income fell to $12.4M (3.2% of sales) from $14.5M (4.0%), and net income came in at $2.6M versus $10.1M. Medical led the growth, up 14% with 9% organic, helped by the Helvoet acquisition, while automotive rose 4% and industrial 5%. Management reiterated fiscal 2027 guidance and now expects sales at the high end of the $1,535-$1,560M range, with adjusted operating income of 4.4%-4.7% and capex of $50-$60M. The sales beat on growth but the earnings miss is the story — margin compression from acquisition costs and a higher tax rate will drive the reaction. The Q1 conference call is scheduled for November 5 at 10:00 AM ET.
At the time of this announcement, KE was trading at $25.86 on NASDAQ in the Technology sector, with a market capitalization of approximately $623.4M. The 52-week trading range was $21.01 to $32.00. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.